Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MOISES ISSA

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1558357780
CMS profile
69935
Location
HOLLYWOOD, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$4,348.67

113 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,662.76 109
Travel and Lodging $1,685.91 4

By paying entity

PY2025 · entire year · sorted by reported total

Page 3 of 3; records 101–113 of 113 matching records. This page contains 13 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MOISES ISSA

NPI 1558357780 · CMS profile ID 69935

Allopathic & Osteopathic Physicians / Internal Medicine

HOLLYWOOD, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–113 of 113 matching records. This page contains 13 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1558357780?year=2025&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MOISES ISSA, NPI 1558357780, CMS profile ID 69935. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–113 of 113 matching records. This page contains 13 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1558357780?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). MOISES ISSA, NPI 1558357780, CMS profile ID 69935. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–113 of 113 matching records. This page contains 13 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1558357780?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
MOISES ISSA, NPI 1558357780, CMS profile ID 69935, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–113 of 113 matching records. This page contains 13 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1558357780?year=2025&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

113 matching records · $4,348.67 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 113 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–113 of 113.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GlaxoSmithKline, LLC. $22.1703/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191319181 CMS
Astellas Pharma US Inc $18.2103/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238762668 CMS
Corcept Therapeutics $22.6402/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1214226179 CMS
Exact Sciences Corporation $25.3702/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235528306 CMS
Lilly USA, LLC $21.4802/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186798075 CMS
Indivior Inc. $21.5402/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240484325 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $20.2602/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231969857 CMS
Bayer Healthcare Pharmaceuticals Inc. $21.0502/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225586999 CMS
Phathom Pharmaceuticals, Inc. $20.9501/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1219349814 CMS
Amgen Inc. $7.7801/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227162836 CMS
Amgen Inc. $17.5701/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228378612 CMS
Exact Sciences Corporation $28.4501/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235528245 CMS
Amgen Inc. $5.4701/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227162846 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $5,274.83 20
PY2020 $379.05 10
PY2021 $1,198.46 55
PY2022 $1,500.75 73
PY2023 $1,165.74 47
PY2024 $3,038.49 92
PY2025 $4,348.67 113

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $736,933.74 19
PY2024 Principal investigator $490,147.68 21
PY2023 Principal investigator $107,749.83 13
PY2022 Principal investigator $97,178.85 12
PY2021 Principal investigator $115,244.17 17
PY2020 Principal investigator $114,054.03 227
PY2019 Principal investigator $294,015.89 216

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

19 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Novartis Pharmaceuticals Corporation $44.78 12/31/2025 Non-covered Recipient Entity
CANO HEALTH HOLLYWOOD
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190308878
Principal investigator 1 Novartis Pharmaceuticals Corporation $43,427.34 12/11/2025 Non-covered Recipient Entity
ZENITH CLINICAL RESEARCH
A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardi No dispute reported 06/30/2026 1190312177
Principal investigator 1 Novartis Pharmaceuticals Corporation $22,091.34 12/02/2025 Non-covered Recipient Entity
ZENITH CLINICAL RESEARCH
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD No dispute reported 06/30/2026 1190312181
Principal investigator 1 AstraZeneca Pharmaceuticals LP $17,080.25 11/14/2025 Non-covered Recipient Entity
ZENITH CLINICAL RESEARCH
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event No dispute reported 06/30/2026 1185550325
Principal investigator 1 Indivior Inc. $2,500.00 11/14/2025 Non-covered Recipient Entity
ZENITH CLINICAL RESEARCH LLC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240469097
Principal investigator 1 Novartis Pharmaceuticals Corporation $13,609.24 11/12/2025 Non-covered Recipient Entity
ZENITH CLINICAL RESEARCH
A multi-center, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study to evaluate efficacy, safety, and tolerability of DII235 in adults with elevated lipoprotein(a) No dispute reported 06/30/2026 1190312167
Principal investigator 1 Novartis Pharmaceuticals Corporation $46,211.95 10/27/2025 Non-covered Recipient Entity
ZENITH CLINICAL RESEARCH
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190312173
Principal investigator 1 Indivior Inc. $394.00 10/02/2025 Non-covered Recipient Entity
ZENITH CLINICAL RESEARCH LLC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468845
Principal investigator 1 Novartis Pharmaceuticals Corporation $9,129.00 08/25/2025 Non-covered Recipient Entity
ZENITH CLINICAL RESEARCH
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190312169
Principal investigator 1 Indivior Inc. $209.50 06/26/2025 Non-covered Recipient Entity
ZENITH CLINICAL RESEARCH LLC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467269
Principal investigator 1 Amgen Inc. $296,777.40 06/08/2025 Non-covered Recipient Entity
ZENITH CLINICAL RESEARCH LLC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity No dispute reported 06/30/2026 1246652416
Principal investigator 1 Indivior Inc. $209.50 04/23/2025 Non-covered Recipient Entity
ZENITH CLINICAL RESEARCH LLC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240465955
Principal investigator 1 Indivior Inc. $209.50 04/02/2025 Non-covered Recipient Entity
ZENITH CLINICAL RESEARCH LLC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240465491
Principal investigator 1 Indivior Inc. $394.00 04/02/2025 Non-covered Recipient Entity
ZENITH CLINICAL RESEARCH LLC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240465493
Principal investigator 1 Novartis Pharmaceuticals Corporation $41,282.53 03/06/2025 Non-covered Recipient Entity
CANO HEALTH HOLLYWOOD
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190308880
Principal investigator 1 Novartis Pharmaceuticals Corporation $74,507.30 01/27/2025 Non-covered Recipient Entity
ZENITH CLINICAL RESEARCH
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190312175
Principal investigator 1 Novartis Pharmaceuticals Corporation $152,514.11 01/17/2025 Non-covered Recipient Entity
ZENITH CLINICAL RESEARCH
A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardi No dispute reported 06/30/2026 1190312179
Principal investigator 1 Novartis Pharmaceuticals Corporation $3,006.00 01/14/2025 Non-covered Recipient Entity
NEXT PHASE RESEARCH ALLIANCE LLC
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190311821
Principal investigator 1 Novartis Pharmaceuticals Corporation $13,336.00 01/07/2025 Non-covered Recipient Entity
ZENITH CLINICAL RESEARCH
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190312171